XEC is a recombinant variant, meaning it’s a hybrid of two previously existing variants. Genomic data suggests it’s making up around 5% of cases in Australia – but it may grow.
Academic rigour, journalistic flair
Articles on SARS-CoV-2
Displaying 1 - 20 of 592 articles
A new study of genetic testing of samples collected from the Huanan Seafood Wholesale Market in Wuhan does not provide definitive clues about COVID origins.
The new COVID variant XEC may be spreading faster than other variants, but it is not a radically different variant.
A new study finds the risks of developing long COVID declined over the first two years of the pandemic. But unvaccinated adults were more than twice as likely to get long COVID compared with those who were vaccinated.
‘FLuQE’ is a direct descendant of the earlier ‘FLiRT’ variants. But an additional mutation could make it more of a worry.
In a human ‘challenge trial’ we deliberately infected volunteers with COVID to get the answer.
Although millions are navigating long COVID, four years into the pandemic both patients and their caregivers continue to face challenges accessing the information and care they need.
Detecting infectious agents in sewage is only the first step. Researchers are working on developing reliable ways to translate surveillance measurements to case numbers and infection predictions.
The so-called ‘FLiRT’ variants are dominant in the US and appear to be gaining traction in Australia. Here’s the information we have so far.
Research shows that rapid antigen tests are performing as well at detecting the most recent dominant variants as they did with the earliest strains in the COVID-19 pandemic.
Two new high-profile studies add to the increasingly worrisome picture of how even mild cases of COVID-19 can have detrimental effects on brain health.
The JN.1 variant has become dominant in Australia and around the world, causing large waves of infections. Here’s what we know about it so far – and why it’s so important.
The current triple epidemic of respiratory viruses is affecting all age groups, prompting comparisons with the pre-COVID-19 era.
As the virus continues to mutate, COVID vaccines are updated. This brings us to the latest announcement about the new ‘monovalent’ vaccines.
This is expected to be the smallest Omicron wave so far. But eligible older and vulnerable people are still recommended to have a booster.
This is an era of exciting advances in medical science. But Africa is in danger of being at the back of the queue once again. What should we be doing to make sure this doesn’t happen?
COVID-19 remains a global public health threat despite its current non-pandemic status.
Australia seems to be focusing on boosters for people aged 75 and over, with its latest recommendations. But that may change.
Only time and data will tell whether the CDC-recommended reformulated shots can stand their ground against the ever-changing SARS-CoV-2 variants.
Researchers still don’t know how well BA.2.86 will evade immunity or whether it will cause more severe disease than its predecessors.
Job Board
-
Operations and Projects Coordinator
-
Economics Editor
-
Deputy Vice-Chancellor (Indigenous Strategy and Services)
-
Chief People & Culture Officer
-
Lecturer / Senior Lecturer in Construction and Project Management
Top contributors
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor, Epidemiology, Deakin University
-
Research Leader in Virology and Infectious Disease, Griffith University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Instructor of Human Immunology, Emory University
-
Professor, Nursing, School of Nursing and Midwifery, Griffith University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Postdoctoral Fellow in Virology and Immunology, University of Colorado Boulder
-
Scientific Officer, University of Leeds
-
Professor of Molecular, Cellular and Developmental Biology, University of Colorado Boulder
-
Lecturer in Virology, Queen's University Belfast
